KR101884634B1 - Lactobacillus fermented drink mixture having weight control effect - Google Patents
Lactobacillus fermented drink mixture having weight control effect Download PDFInfo
- Publication number
- KR101884634B1 KR101884634B1 KR1020170017318A KR20170017318A KR101884634B1 KR 101884634 B1 KR101884634 B1 KR 101884634B1 KR 1020170017318 A KR1020170017318 A KR 1020170017318A KR 20170017318 A KR20170017318 A KR 20170017318A KR 101884634 B1 KR101884634 B1 KR 101884634B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- fermentation broth
- lactobacillus
- strain
- acid fermentation
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims abstract description 21
- 235000019985 fermented beverage Nutrition 0.000 title claims abstract description 9
- 238000004260 weight control Methods 0.000 title claims abstract 3
- 241000186660 Lactobacillus Species 0.000 title description 7
- 229940039696 lactobacillus Drugs 0.000 title description 6
- 239000000203 mixture Substances 0.000 title description 2
- 238000000855 fermentation Methods 0.000 claims abstract description 82
- 230000004151 fermentation Effects 0.000 claims abstract description 82
- 235000008429 bread Nutrition 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 241000186610 Lactobacillus sp. Species 0.000 claims abstract description 20
- 239000008213 purified water Substances 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 19
- 235000020824 obesity Nutrition 0.000 claims abstract description 19
- 239000006041 probiotic Substances 0.000 claims abstract description 15
- 235000018291 probiotics Nutrition 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 163
- 239000004310 lactic acid Substances 0.000 claims description 81
- 235000014655 lactic acid Nutrition 0.000 claims description 81
- 238000012360 testing method Methods 0.000 claims description 37
- 241000894006 Bacteria Species 0.000 claims description 22
- 229930091371 Fructose Natural products 0.000 claims description 17
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000005715 Fructose Substances 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 10
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 241000192132 Leuconostoc Species 0.000 claims description 5
- 230000003908 liver function Effects 0.000 claims description 5
- 241000235070 Saccharomyces Species 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 108010030696 low density lipoprotein triglyceride Proteins 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 36
- 229960002737 fructose Drugs 0.000 description 15
- 235000013361 beverage Nutrition 0.000 description 11
- 230000001276 controlling effect Effects 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012813 breadcrumbs Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D13/00—Finished or partly finished bakery products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/31—Leuconostoc
-
- A23Y2220/00—
-
- A23Y2260/00—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 비만 예방 및 체중 조절 효과를 지닌 유산균 발효액 및 이를 원료로 사용한 발효 음료에 관한 것이다. 더욱 상세하게는 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말에 정제수 및 당류를 넣고 당도를 조절시킨 후 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액을 넣어 발효 숙성시킨 유산균 발효액 및 이를 원료로 사용한 발효 음료에 관한 것이다.
The present invention relates to a lactic acid fermentation broth having an effect of preventing obesity and controlling body weight and a fermented beverage using the same as a raw material. More specifically, the bread prepared with the probiotic agent is dried and pulverized. Purified water and saccharides are added to the obtained bread powder, and the sugar content is adjusted. The lactic acid bacteria fermented and aged by adding a culture solution of Lactobacillus sp. Nhs221 (Deposit No. KCTC-11749BP) And a fermented beverage using the same as a raw material.
현대인들은 고열량의 식사가 주를 이루는 식생활의 변화 및 운동 부족, 스트레스의 증가에 의해 인체의 항상성이 교란되고 있으며, 이에 따라 각종 비만 및 관련 대사성 질환이 급증하고 있다. 관련 대사성 질환은 2형 당뇨병 및 고혈압뿐 아니라, 뇌졸중, 동맥경화 등 심혈관 질환과 각종 암에 이르기까지 인류의 건강 및 생명을 위협하는 심각한 질환을 포함한다.
Modern people are disturbed by homeostasis of the human body due to changes in dietary habits, lack of exercise, and stress, which lead to high calorie meals, and various obesity and related metabolic diseases are increasing rapidly. Related metabolic diseases include not only type 2 diabetes and hypertension but also serious health and life-threatening diseases such as stroke, arteriosclerosis, cardiovascular diseases and various cancers.
20세기 후반에 비하면 비만율은 5~10배 증가하였다. 특히 중??장년층의 복부비만은 만성 대사 증후군의 직접적인 원인이 될 수 있어 항상 주의가 필요하다. 특히 복부 비만의 경우는 지방이 쉽게 용해되어 혈액 속에 흡수되므로 대사 증후군의 원인이 될 수 있다.
Compared with the latter half of the 20th century, obesity rates increased 5 to 10 times. Abdominal obesity in middle-aged middle-aged people can be a direct cause of chronic metabolic syndrome. Especially in abdominal obesity, the fat is easily dissolved and absorbed into the blood, which can cause the metabolic syndrome.
세계보건기구(WHO)에서는 1996년도에 비만을 질병으로 분류하고, 이를 예방 내지 치료해야 할 대상으로 명시하였다.
The World Health Organization (WHO) classified obesity as a disease in 1996 and specified it as an object to be prevented or treated.
현재까지 알려진 비만치료제로는 제니칼(Xenical), 리덕틸(Reductil), 엑소리제(Exolise) 등으로 크게 식욕억제제, 에너지소비 촉진제, 지방흡수억제제로 분류되며 대부분의 비만치료제는 시상하부와 관련된 신경전달물질을 조절함으로써 식욕을 억제하는 식욕억제제이다.
Xenical, Reductil, and Exolise are classified as appetite suppressants, energy consumption stimulators, and fat absorption inhibitors, and most of the obesity drugs are hypothalamic-related neurotransmitters Is an appetite suppressant that suppresses appetite.
현재까지 개발된 치료제들은 심장질환, 호흡기질환, 신경계질환 등의 부작용과 함께 그 효능의 지속성도 낮아, 더욱 개선된 비만치료제의 개발이 필요하고 또한 현재 개발되고 있는 제품도 부작용 없이 만족할 만한 치료효과를 가지는 치료제는 없어 새로운 비만치료제의 개발이 요구되고 있다.
The therapeutic agents developed so far have not only the side effects such as heart disease, respiratory diseases and neurological diseases but also the persistence of their efficacy is low and it is necessary to develop more improved therapeutic agents for obesity and the products which are currently being developed have satisfactory therapeutic effects without side effects There is no cure for the disease, and development of a new treatment for obesity is required.
최근 비피도박테리아 균주를 포함하는 살아있는 미생물 제제인 생균제(프로바이오틱스)를 사용하여 비만 관련 치료 및 예방을 위한 제제가 개발되고 있다.
Recently, agents for the treatment and prevention of obesity have been developed by using probiotics (probiotics), which are living microbial agents containing Bifidobacterium strains.
그런데 이러한 생균제를 비만 관련 치료 및 예방용으로 직접 복용할 경우 급격한 장 내 박테리아 생태계에 변화를 주어 장 내의 유산균 수를 일시적으로 감소시킬 수도 있어 장 내 연동운동을 감소시키고 이에 따라 변비 등을 유발할 수 있는 문제점이 있었던 것이다.
However, when these probiotics are directly used for the treatment and prevention of obesity, it is possible to temporarily reduce the number of lactic acid bacteria in the intestines by changing the intestinal bacterial ecosystem, thereby reducing intestinal peristalsis and thus causing constipation There was a problem.
이에 본 발명자는 상기와 같은 생균제제의 문제점을 해결하기 위해 생균제제보다 생균제제를 사용하여 발효시킨 기능성 발효액을 개발하던 중 본 발명자가 이미 개발하여 상용화시킨 대한민국 특허등록 제10-923,051호 '기능성 생균제제 및 이를 이용하여 제조된 빵'을 주재료로 하고 정제수를 첨가시켜 혼합액을 제조한 후 여기에 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액을 첨가 발효 숙성시켜 유산균 발효액을 제조하고 상기 수득된 발효액의 비만 예방 및 체중 조절 효과를 확인함으로써 본 발명을 완성하게 된 것이다.
Accordingly, the inventor of the present invention developed a functional fermentation broth using fermentation broth using a probiotics rather than a probiotics agent to solve the problems of the probiotics as described above. The inventors of the present invention have developed and commercialized Korean Patent No. 10-923,051 ' (Manufactured by KCTC-11749BP) is added to fermentation broth to prepare a lactic acid fermentation broth, and a lactic acid fermentation broth is prepared by adding fermented broth to the broth. The present invention has been accomplished by confirming the effect of preventing fermentation of obesity and regulating body weight.
본 발명이 해결하고자 하는 과제는 본 발명자의 기능성 생균제제를 이용하여 제조된 빵을 주재료로 하고 정제수를 첨가시켜 혼합액을 제조한 후 여기에 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액을 첨가 발효 숙성시킨 유산균 발효액을 개발코자 한 것이다. 또한 상기 유산균 발효액의 비만 예방 및 체중 조절 효과를 측정코자 한 것이다.
A problem to be solved by the present invention is to prepare a mixed solution by adding purified water to the bread prepared using the functional biocide of the present inventor as a main ingredient and then adding a culture solution of Lactobacillus sp. Nhs221 (Deposit No. KCTC-11749BP) And to develop a fermentation broth of fermented lactic acid bacteria. In addition, it is intended to measure the effect of preventing the lactic acid fermentation broth and controlling the body weight.
본 발명의 목적은 ⅰ) 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100 중량부에 대해 정제수 300~700 중량부를 넣고 설탕 및/또는 과당을 첨가하여 10~15°Brix 농도로 당도를 조절하는 단계; 및 ⅱ) 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 0.8~1.2 중량부(1.0 ~ 8.0 ×108 cfu/ml)를 넣어 실온에서 50~100일간 발효 숙성시켜 유산균 발효액을 수득하는 단계;로 이루어진 유산균 발효액의 제조 방법에 있어서, 상기 생균제제는 류코노스톡(Leuconostoc) 속의 생균주(기탁번호 KCTC-11226BP호)와 사카로마이세스(Saccharomyces) 속의 효모균주(기탁번호 KCTC-11227BP호)를 혼합시킨 생균제제임을 특징으로 하는 비만 예방 및 체중 조절 효과를 지닌 유산균 발효액의 제조 방법을 제공하는 것이다.
The object of the present invention is to provide a method for preparing a bread crumb, comprising: i) 300 to 700 parts by weight of purified water is added to 100 parts by weight of bread powder obtained by drying and pulverizing bread prepared with a probiotic agent, sugar and / or fructose are added, ; And (ii) 0.8 to 1.2 parts by weight (1.0 to 8.0 × 10 8 cfu / ml) of a culture broth of Lactobacillus sp. Nhs221 (accession number KCTC-11749BP) is fermented at room temperature for 50 to 100 days to obtain a lactic acid fermentation broth Wherein the probiotic agent is a yeast strain of Leuconostoc (Accession No. KCTC-11226 BP) and a strain of Saccharomyces (Accession No. KCTC-11227 BP) The present invention also provides a method for producing a lactic acid fermentation broth having an effect of preventing obesity and controlling body weight.
또한 상기 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)는 락토바실러스속 균주로서 전분 배지 내에서 다량의 락트산을 발효 생성하는 균주임을 특징으로 한다.
The Lactobacillus sp. Nhs221 strain (Accession No. KCTC-11749BP) is a lactobacillus strain strain, which is a strain that fermentes a large amount of lactic acid in a starch medium.
한편 상기 유산균 발효액은 시험동물 내에서 총 콜레스테롤, 고밀도 리포단백질 콜레스테롤, 저밀도 리포단백질 콜레스테롤 및 트리글리세라이드의 함량을 저하시켜 간 기능 개선 효과가 있음을 특징으로 한다.
On the other hand, the lactic acid fermentation broth is characterized in that the content of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglyceride is lowered in the test animal to improve liver function.
본 발명의 또 다른 목적은 상기 방법에 따라 제조된 유산균 발효액에 올리고당, 과당 및 정제수를 첨가하여 제조된 비만 예방 및 체중 조절 효과를 지닌 유산균 발효 음료를 제공하는 것이다.
Another object of the present invention is to provide a fermented beverage of lactic acid bacteria having an effect of preventing obesity and controlling body weight, which is prepared by adding oligosaccharide, fructose and purified water to a lactic acid fermentation broth produced according to the above method.
본 발명의 효과는 본 발명자의 기능성 생균제제를 이용하여 제조된 빵을 주재료로 하고 정제수를 첨가시켜 혼합액을 제조한 후 여기에 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액을 첨가 발효 숙성시킨 유산균 발효액을 제공하는 것이다. 또한 상기 유산균 발효액의 비만 예방 및 체중 조절 효과를 제공하는 것이다.
The effect of the present invention is that the bread prepared using the functional biocide of the present inventor is used as a main ingredient and purified water is added thereto to prepare a mixed solution, and then a culture solution of Lactobacillus sp. Nhs221 (Accession No. KCTC-11749BP) To thereby provide a fermented broth of lactic acid bacteria. The present invention also provides a method of preventing obesity and controlling body weight of the lactic acid fermentation broth.
본 발명은 ⅰ) 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100 중량부에 대해 정제수 300~700 중량부를 넣고 설탕 및/또는 과당을 첨가하여 10~15°Brix 농도로 당도를 조절하는 단계; 및 ⅱ) 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 0.8~1.2 중량부(1.0 ~ 8.0 ×108 cfu/ml)를 넣어 실온에서 50~100일간 발효 숙성시켜 유산균 발효액을 수득하는 단계;로 이루어진 유산균 발효액의 제조 방법에 있어서, 상기 생균제제는 류코노스톡(Leuconostoc) 속의 생균주(기탁번호 KCTC-11226BP호)와 사카로마이세스(Saccharomyces) 속의 효모균주(기탁번호 KCTC-11227BP호)를 혼합시킨 생균제제임을 특징으로 하는 비만 예방 및 체중 조절 효과를 지닌 유산균 발효액의 제조 방법에 관한 것이다.
The present invention relates to a method for controlling sugar content, comprising: i) 300 to 700 parts by weight of purified water is added to 100 parts by weight of bread powder obtained by drying and pulverizing bread prepared with a probiotics preparation, sugar and / or fructose are added, ; And (ii) 0.8 to 1.2 parts by weight (1.0 to 8.0 × 10 8 cfu / ml) of a culture broth of Lactobacillus sp. Nhs221 (accession number KCTC-11749BP) is fermented at room temperature for 50 to 100 days to obtain a lactic acid fermentation broth Wherein the probiotic agent is a yeast strain of Leuconostoc (Accession No. KCTC-11226 BP) and a strain of Saccharomyces (Accession No. KCTC-11227 BP) The present invention relates to a method for producing a lactic acid fermentation broth having an effect of preventing obesity and controlling body weight.
이하 본 발명을 더욱 상세히 설명한다.
Hereinafter, the present invention will be described in more detail.
본 발명의 유산균 발효액 제조에 접종되는 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)는 락토바실러스속 균주로서 전분 배지 내에서 다량의 락트산을 발효 생성하는 균주이다.
The Lactobacillus sp. Nhs221 strain (Accession No. KCTC-11749BP) inoculated into the lactic acid fermentation broth of the present invention is a lactobacillus strain strain that fermentes a large amount of lactic acid in the starch medium.
표 1은 본 발명의 분리된 유산균주 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)의 분리 동정 자료이다. 일반적 균학적 특성이 락토바실러스속 균주와 거의 유사하였다. 그러나 통상의 락토바실러스속 균주와는 달리 전분 배지 내에서 많은 양의 락트산을 발효 생성하는 신균주이므로 본 균주를 락토바실러스속 nhs221이라 명명하고 대전광역시 유성구 어은동 52번지 생명공학연구원 내의 Korean Collection for Type Cultures에 2010년 8월 24일자로 기탁번호 KCTC-11749BP호로 기탁하였다.
Table 1 shows the isolation and identification data of the isolated strains of lactic acid bacteria Lactobacillus nhs221 (Accession No. KCTC-11749BP). The general mycological characteristics were similar to those of Lactobacillus spp. However, unlike the conventional Lactobacillus sp. Strain, this strain is a new strain producing fermentation of a large amount of lactic acid in the starch medium. Therefore, this strain is designated as Lactobacillus sp. Nhs221 and the Korean Collection for Type Cultures Deposited on August 24, 2010 under accession number KCTC-11749BP.
일반적 특성Of Lactobacillus sp.
General characteristics
(기탁번호 KCTC-11749BP호)The strain of the present invention
(Accession No. KCTC-11749BP)
d는 지연된 반응을 나타냄
d represents a delayed response
한편 본 발명의 발효액은 시험동물 내에서 총 콜레스테롤, 고밀도 리포단백질 콜레스테롤, 저밀도 리포단백질 콜레스테롤 및 트리글리세라이드의 함량을 저하시켜 간 기능 개선 효과를 지닌다.
Meanwhile, the fermentation broth of the present invention has an effect of improving liver function by lowering the contents of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglyceride in test animals.
본 발명의 이러한 비만 예방 및 체중 조절 효과와 간 기능 개선 효과는 빵 제조시 사용된 생균제제인 류코노스톡(Leuconostoc) 속의 생균주(기탁번호 KCTC-11226BP호)와 사카로마이세스(Saccharomyces) 속의 효모균주(기탁번호 KCTC-11227BP호)를 혼합시킨 생균제제와 본 발명의 유산균 발효액 제조에 사용되는 유산균주인 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)와의 상승적 복합 생균제제 효과로 여겨진다.
The effect of preventing obesity and controlling body weight and improving liver function of the present invention can be attained by adding a live yeast strain of Leuconostoc (Accession No. KCTC-11226BP), a yeast strain of Saccharomyces, (Deposit No. KCTC-11227BP) and the lactic acid bacteria belonging to the genus Lactobacillus nhs221 (Accession No. KCTC-11749BP) used in the lactic acid bacteria fermentation broth of the present invention for producing the lactic acid bacteria fermentation broth of the present invention.
이러한 본 발명의 유산균 발효액은 그대로 음용할 수도 있으나 예를 들면 빵, 초콜렛, 과자, 라면, 아이스크림, 육가공 제품, 낙농 제품 등과 같은 다른 식품 또는 올리고당, 과당 또는 설탕과 같은 정량의 감미료, 향미료, 비타민, 무기질 및 색소 등을 첨가하여 유산균 발효 음료로 개발 음용할 수도 있다.
The lactic acid fermentation broth of the present invention may be used as it is, but it may be used as it is for other foods such as bread, chocolate, confectionery, ramen, ice cream, meat products and dairy products, or a sweetener of a certain amount such as oligosaccharide, Minerals and pigments may be added to be developed into lactic acid bacteria fermented beverages.
이때 본 발명의 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)의 함량은 식품 소재 1g 당 0.1 ~ 100 × 108 cfu 정도이다.
At this time, the content of the Lactobacillus sp. Nhs221 strain of the present invention (Accession No. KCTC-11749BP) is about 0.1 to 100 × 10 8 cfu per 1 g of the food material.
특히 유산균 발효액에 올리고당, 과당 및 정제수를 첨가하여 비만 예방 및 체중 조절 효과를 지닌 유산균 발효 음료로 음용하는 것이 바람직하다.
In particular, it is preferable to add oligosaccharide, fructose and purified water to the fermentation broth of lactic acid bacteria to drink it as a lactic acid fermented beverage having an effect of preventing obesity and controlling body weight.
또한 본 발명의 유산균 발효액에는 약제학적으로 허용되는 통상의 담체, 부형제 및 희석제를 포함시켜 의약품 제제 형태로 개발, 투여, 복욕할 수 있다.
In addition, the lactic acid fermentation broth of the present invention can be developed, administered, and bathed in the form of pharmaceutical preparations including conventional pharmaceutically acceptable carriers, excipients and diluents.
이러한 본 발명의 유산균 발효액의 투여 용량은 복용자의 상태, 연령, 성별 및 질환 정도 등의 다양한 요인에 따라 결정될 수 있지만 통상 성인 1kg/day 당 0.5~20ml, 바람직하게는 5~10ml 정도이며 이때 1ml 당 유산균 함유량은 0.1 ~ 200 × 108 cfu이다.
The dosage of the lactic acid fermentation broth of the present invention may be determined according to various factors such as the condition of the recipient, age, sex and disease severity, but is usually 0.5 to 20 ml, preferably 5 to 10 ml per 1 kg / day of an adult, The content of lactic acid bacteria is 0.1 to 200 x 10 8 cfu.
이하 본 발명을 준비예, 제조실시예, 제조비교예 및 실시예를 통해 더욱 상세히 설명한다.
Hereinafter, the present invention will be described in more detail through Preparation Examples, Production Examples, Comparative Production Examples and Examples.
(준비예 1) 생균 제제로 제조된 빵
(Preparation Example 1) Bread prepared from a live bacterial preparation
밀가루 반죽 100g에 중량부에 류코노스톡(Leuconostoc) 속의 생균주(기탁번호 KCTC-11226BP호) 0.2g와 사카로마이세스(Saccharomyces) 속의 효모균주(기탁번호 KCTC-11227BP호) 0.2g를 첨가 발효시킨 후 오븐에서 구워 빵을 제조한다. 이 때 밀가루 반죽은 밀가루 40g, 물 58g, 기타 식염, 설탕, 아미노산, 포도당 등의 첨가 성분 2g으로 구성되어 있다. 이는 본 발명자의 이전 등록 특허인 대한민국 등록특허 제10-923051호 '기능성 생균제제 및 이를 이용하여 제조된 빵'에 개시된 방법에 따라 생균 제제로 빵을 제조한 것이다.
To 100 g of wheat flour, 0.2 g of a live stock strain of Leuconostoc (Deposit No. KCTC-11226BP) and 0.2 g of yeast strain of Saccharomyces sp. (Accession No. KCTC-11227BP) And baked in an oven to make bread. At this time, the flour dough is composed of 2g of flour, 40g of water, 58g of water, and other ingredients such as salt, sugar, amino acid and glucose. This is a bread made from a live-prepared preparation according to the method disclosed in Korean Patent No. 10-923051, "Functional Probiotic Agent and Bread Made Using the Active Bacteria Agent", which was previously registered by the present inventor.
(준비예 2) 본 발명의 유산균주의 분리
(Preparation Example 2) Separation of lactic acid bacteria of the present invention
빵 제조용 스폰지에 천연 과일 액즙을 첨가시킨 후 1주 동안 상온에서 방치하면 공기 중의 미생물이 스폰지에 붙어 발효 배양된다. 발효 배양된 스폰지를 건조시킨 후 상온에서 혐기성 조건 하에 2~3일 경과시키면서 미생물의 생장을 촉진시킨다. 미생물이 함유된 건조 스폰지를 잘게 분쇄시킨 후 평판 플레이트에 넣고 평판 플레이트에서 분쇄된 건조 스폰지 5mg씩을 10군데에서 분리 취득한다.
When the natural fruit juice is added to the sponge for making bread and left at room temperature for 1 week, microorganisms in the air are fermented and attached to the sponge. Fermentation The cultured sponge is dried and incubated at room temperature under anaerobic conditions for 2 to 3 days to promote the growth of microorganisms. The dry sponge containing microorganisms is finely pulverized and placed in a flat plate, and 5 mg of pulverized dried sponge is separated and collected in 10 places on a flat plate.
취득된 10군데의 분쇄 건조 스폰지 5mg씩을 10개의 배양 접시에 나누어 넣고, 배양 접시에 5g의 전분 배지를 첨가시킨 후, 20℃, 75% 습도 조건 하에서 48시간 배양시켜 10개의 배양 접시 중 가장 많은 락트산이 발효 생성된 배양 접시를 선별하고 그 균주를 분리하였다.
5 mg of each of the obtained 10 pieces of crushed and dried sponges was placed in 10 culture dishes and 5 g of starch medium was added to the culture dish and cultured for 48 hours at 20 ° C. and 75% humidity to obtain the lactic acid The fermentation-generated culture dish was selected and the strain was isolated.
이때 분리된 균주는 효모 균주와 유산균 균주의 혼합 상태로 존재하였으며 그 중 유산균주 만을 분리 동정하여 본 발명의 유산균 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호)를 분리하였다.
At this time, the isolated strain was present in a mixed state of the yeast strain and the lactic acid bacterium strain. Among them, only the lactic acid bacteria strain was isolated and identified to isolate the lactic acid bacterium Lactobacillus sp. Nhs221 strain (Accession No. KCTC-11749BP) of the present invention.
(비교준비예 1) 화학적 팽창제로 제조된 빵
(Comparative Preparation Example 1) Bread prepared with a chemical swelling agent
밀가루 반죽 100g에 중량부에 화학적 팽창제인 베이킹파우더를 0.5g 첨가하여 오븐에서 구워 빵을 제조한다. 이 때 밀가루 반죽은 밀가루 40g, 물 58g, 기타 식염, 설탕, 아미노산, 포도당 등의 첨가 성분 2g으로 구성되어 있다.
0.5 g of baking powder, which is a chemical swelling agent, is added to parts by weight of 100 g of flour dough and baked in an oven to prepare bread. At this time, the flour dough is composed of 2g of flour, 40g of water, 58g of water, and other ingredients such as salt, sugar, amino acid and glucose.
(제조실시예 1) 본 발명의 유산균 발효액의 제조 (숙성기간 60일)
(Production Example 1) Production of lactic acid bacteria fermentation broth of the present invention (fermentation period: 60 days)
준비예 1에서 제조된 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100g에 정제수 500ml를 넣고 여기에 적정 당도를 유지하기 위해 설탕, 과당 등을 적량 넣어 12°Brix 농도로 당도를 조절하고 준비예 2에서 분리된 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 1ml(1.0 ~ 8.0 ×108 cfu)를 넣어 실온에서 60일간 발효 숙성시켜 본 발명의 유산균 발효액을 수득한다.
500 ml of purified water was added to 100 g of the bread powder obtained by drying the prepared bread prepared in Preparatory Example 1, and the resulting bread was pulverized. To maintain the sugar content, 100 g of sugar, fructose and the like were added thereto to adjust the sugar content to 12 ° Brix 1 ml (1.0 to 8.0 × 10 8 cfu) of the culture broth of Lactobacillus sp. Nhs221 (Accession No. KCTC-11749BP) isolated in Preparation Example 2 was added and fermentation was performed at room temperature for 60 days to obtain a lactic acid fermentation broth of the present invention.
(제조실시예 2) 본 발명의 유산균 발효액의 제조 (숙성기간 90일)
(Preparation Example 2) Preparation of fermentation broth of lactic acid bacteria of the present invention (fermentation period: 90 days)
준비예 1에서 제조된 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100g에 정제수 500ml를 넣고 여기에 적정 당도를 유지하기 위해 설탕, 과당 등을 적량 넣어 12°Brix 농도로 당도를 조절하고 준비예 2에서 분리된 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 1ml(1.0 ~ 8.0 ×108 cfu)를 넣어 실온에서 90일간 발효 숙성시켜 본 발명의 유산균 발효액을 수득한다.
500 ml of purified water was added to 100 g of the bread powder obtained by drying the prepared bread prepared in Preparatory Example 1, and the resulting bread was pulverized. To maintain the sugar content, 100 g of sugar, fructose and the like were added thereto to adjust the sugar content to 12 ° Brix 1 ml (1.0 to 8.0 × 10 8 cfu) of the culture broth of Lactobacillus sp. Nhs221 (Accession No. KCTC-11749BP) isolated in Preparation Example 2 was added and fermentation was performed at room temperature for 90 days to obtain a lactic acid fermentation broth of the present invention.
(제조비교예 1) 유산균 발효액의 제조 (화학적 팽창제로 제조된 빵)
(Production Comparative Example 1) Preparation of Lactic Acid Bacteria Fermentation Liquid (Bread Prepared with Chemical Expansive Agent)
비교준비예 1에서 제조된 화학적 팽창제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100g에 정제수 500ml를 넣고 여기에 적정 당도를 유지하기 위해 설탕, 과당 등을 적량 넣어 12°Brix 농도로 당도를 조절하고 준비예 2에서 분리된 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 1ml(1.0 ~ 8.0 ×108 cfu)를 넣어 실온에서 60일간 발효 숙성시켜 유산균 발효액을 수득한다.
500 ml of purified water was added to 100 g of the bread powder obtained by drying and pulverizing the bread prepared with the chemical swelling agent prepared in Comparative Example 1. To maintain the sugar content, 100 g of sugar, fructose and the like were added thereto at a concentration of 12 ° Brix And 1 ml (1.0 to 8.0 x 10 8 cfu) of the culture broth of Lactobacillus sp. Nhs221 (Accession No. KCTC-11749BP) isolated in Preparation Example 2 was added thereto and fermentation was performed at room temperature for 60 days to obtain a lactic acid fermentation broth.
(제조비교예 2) 유산균 발효액의 제조 (발효 숙성 기간의 차이)
(Preparation Comparative Example 2) Preparation of lactic acid fermentation broth (difference in fermentation period of fermentation)
준비예 1에서 제조된 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100g에 정제수 500ml를 넣고 여기에 적정 당도를 유지하기 위해 설탕, 과당 등을 적량 넣어 12°Brix 농도로 당도를 조절하고 준비예 2에서 분리된 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 1ml(1.0 ~ 8.0 ×108 cfu)를 넣어 실온에서 15일간 발효 숙성시켜 유산균 발효액을 수득한다.
500 ml of purified water was added to 100 g of the bread powder obtained by drying the prepared bread prepared in Preparatory Example 1, and the resulting bread was pulverized. To maintain the sugar content, 100 g of sugar, fructose and the like were added thereto to adjust the sugar content to 12 ° Brix 1 ml (1.0 to 8.0 x 10 8 cfu) of the culture broth of Lactobacillus sp. Nhs221 (Accession No. KCTC-11749BP) isolated in Preparation Example 2 was added and fermentation was carried out at room temperature for 15 days to obtain a lactic acid fermentation broth.
(제조비교예 3) 유산균 발효액의 제조 (유산균의 차이)
(Preparation Comparative Example 3) Preparation of lactic acid fermentation broth (Difference in lactic acid bacteria)
준비예 1에서 제조된 생균제제로 제조된 빵을 건조시킨 후 분쇄시켜 수득된 빵 분말 100g에 정제수 500ml를 넣고 여기에 적정 당도를 유지하기 위해 설탕, 과당 등을 적량 넣어 12°Brix 농도로 당도를 조절하고 발효유 제조에 사용되는 상업적으로 구매 가능한 유산균 락토바실러스 람노서스 GG 배양액 1ml(1.0 ~ 8.0 ×108 cfu)를 넣어 실온에서 60일간 발효 숙성시켜 유산균 발효액을 수득한다.
500 ml of purified water was added to 100 g of the bread powder obtained by drying the prepared bread prepared in Preparatory Example 1, and the resulting bread was pulverized. To maintain the sugar content, 100 g of sugar, fructose and the like were added thereto to adjust the sugar content to 12 ° Brix 1 ml (1.0 to 8.0 x 10 8 cfu) of a commercially available lactobacillus lambusaceus Lamb- nosus GG culture used for fermented milk production is added and fermented for 60 days at room temperature to obtain a lactic acid fermentation broth.
(실시예)
(Example)
(시험동물의 순화 및 급이)
(Purification and Feeding of Test Animals)
시험동물은 3주령의 웅성 SD(스프라그-돌리) 래트를 사용하였다. 각 시험군은 4마리의 래트를 2마리씩 하나의 케이지에 넣어 시험하였다. 물은 표준 급이하였으며 식이는 1주간 표준식이 제공 후 고지방 식이와 시험용 유산균 발효액을 5주간 급이하였다. 1일 섭취 고지방 식이의 성분 및 열량은 다음과 같다.
Test animals used male SD (Sprague-Dolly) rats at 3 weeks of age. Each test group was tested by placing two rats in a single cage. Water was standard grade and diet was fed with high fat diet and lactic acid fermentation broth for 5 weeks after 1 week of standard diet. Ingredients and calories of high-fat diets consumed per day are as follows.
(고지방 식이의 성분 및 열량)
(Components and calories in high fat diets)
카제인 200g 720kcal, 우지 400g 3600kcal, 메티오닌 3g 12kcal, 전분 150g 540kcal, 설탕 150g 600kcal, 셀룰로스 50g 0kcal, 염분 혼합물 35g 30.8kcal, 비타민 혼합물 10g 39kcal, 타타르산수소콜린 2g 0kcal, 총 5541.8kcal.
Casein 200g 720kcal, Uji 400g 3600kcal, methionine 3g 12kcal, starch 150g 540kcal, sugar 150g 600kcal, cellulose 50g 0kcal, salt mixture 35g 30.8kcal, vitamin mixture 10g 39kcal, tartaric acid choline 2g 0kcal, total 5541.8kcal.
(시험군 1) 본 발명의 제조실시예 1에서 제조된 유산균 발효액 1ml와 생리식염수(PBS) 1ml를 혼합시킨 후 혼합된 유산균 발효액 0.2ml를 급이하였다.
(Test group 1) 1 ml of the lactic acid fermentation broth prepared in Preparation Example 1 of the present invention and 1 ml of physiological saline (PBS) were mixed, and 0.2 ml of the mixed lactic acid fermentation broth was added.
(비교시험군 1) 제조비교예 1에서 제조된 유산균 발효액 1ml와 생리식염수(PBS) 1ml를 혼합시킨 후 혼합된 유산균 발효액 0.2ml를 급이하였다.
(Comparative Test Group 1) Preparation 1 ml of the lactic acid fermentation broth prepared in Comparative Example 1 and 1 ml of physiological saline (PBS) were mixed and then 0.2 ml of the mixed lactic acid fermentation broth was added.
(비교시험군 2) 제조비교예 2에서 제조된 유산균 발효액 1ml와 생리식염수(PBS) 1ml를 혼합시킨 후 혼합된 유산균 발효액 0.2ml를 급이하였다.
(Comparative Test Group 2) Preparation 1 ml of the lactic acid fermentation broth prepared in Comparative Example 2 and 1 ml of physiological saline (PBS) were mixed and then 0.2 ml of the mixed lactic acid fermentation broth was added.
(비교시험군 3) 제조비교예 3에서 제조된 유산균 발효액 1ml와 생리식염수(PBS) 1ml를 혼합시킨 후 혼합된 유산균 발효액 0.2ml를 급이하였다.
(Comparative Test Group 3) Preparation 1 ml of the lactic acid fermentation broth prepared in Comparative Example 3 and 1 ml of physiological saline (PBS) were mixed, and 0.2 ml of the mixed lactic acid fermentation broth was added.
(대조군) 생리식염수(PBS) 0.2ml 만을 급이하였다.
(Control) 0.2 ml of physiological saline solution (PBS).
(실시예 1) 다이어트 식이 조절 효과의 측정
(Example 1) Measurement of the effect of controlling diet diet
시험군 1, 비교시험군 1, 비교시험군 2, 비교시험군 3, 대조군에 각각 5주간 고지방 식이와 유산균 발효액 0.2ml를 급이시킨 후 식이 조절에 따른 체중 변화를 5일 간격으로 측정하여 그 시험결과를 표 2에 나타내었다.
After feeding high fat diet and 0.2 ml of fermented lactic acid fermentation for 5 weeks to each of the test group 1, the comparative test group 1, the comparative test group 2, the comparative test group 3, and the control group, the weight change according to the dietary control was measured at intervals of 5 days The test results are shown in Table 2.
고지방 식이와 본 발명의 유산균 발효액 0.2ml를 5주간 급이한 시험군 1의 경우 35일 후 체중은 약 230g 증가하였으며 고지방 식이와 생리식염수 0.2ml만을 5주간 급이한 대조군의 경우 체중은 약 245g 증가하였다. 따라서 시험군 1의 경우 대조군보다 약 6 중량%의 증체량 감소를 나타내었다. 이는 본 발명의 유산균 발효액의 급이가 고지방 식이에도 불구하고 증체량을 감소시키는 다이어트 식이 조절 효과가 있음을 나타내는 것이다.
In the case of the test group 1 in which 0.2 ml of the lactic acid fermentation broth of the present invention was fed for 5 weeks, the body weight was increased by about 230 g after 35 days. In the case of the control group in which only the 0.2 ml of high fat diet and physiological saline was fed for 5 weeks, the body weight was about 245 g Respectively. Therefore, in the test group 1, the weight loss was decreased by about 6% by weight compared to the control group. This indicates that the feeding of the lactic acid fermentation broth of the present invention has a regulating effect on diet diet which reduces the amount of body weight despite the high fat diet.
한편 고지방 식이와 함께 제조비교예 1, 2, 3에서 제조된 유산균 발효액 0.2ml를 5주간 급이한 비교시험군 1, 비교시험군 2 및 비교시험군 3의 경우 대조군에 비해 유의미한 증체량의 변화를 나타내지 않았으며 이는 제조비교예 1, 2, 3에서 제조된 유산균 발효액의 경우 유의미한 다이어트 식이 조절 효과를 나타내지 않음을 의미하는 것이다.
On the other hand, in the comparative test group 1, the comparative test group 2 and the comparative test group 3 in which 0.2 ml of the lactic acid fermentation broth prepared in Comparative Production Examples 1, 2 and 3 were fed for 5 weeks together with the high fat diet, significant changes in the body weight gain This means that the lactic acid fermentation broth prepared in Preparation Comparative Examples 1, 2 and 3 does not show a significant effect of regulating the diet.
(실시예 2) 간기능 개선 효과의 측정
(Example 2) Measurement of liver function improving effect
5주간 시험기간 종료 후 시험군 1, 비교시험군 1, 2, 3, 대조군의 각각의 래트에서 혈액을 채취하여 그 혈청을 분리 후 총 콜레스테롤(TC), 고밀도 리포단백질 콜레스테롤(HDL-C), 저밀도 리포단백질 콜레스테롤(LDL-C), 트리글리세라이드 및 글루코스 함량을 측정하였다. 그 결과를 표 3에 나타내었다.
(TC), high density lipoprotein cholesterol (HDL-C), and high-density lipoprotein cholesterol (HDL-C) after the blood samples were taken from the rats of the test group 1, Low density lipoprotein cholesterol (LDL-C), triglyceride and glucose content were measured. The results are shown in Table 3.
(단위 : mg/dl)
(Unit: mg / dl)
고지방 식이와 본 발명의 유산균 발효액 0.2ml를 5주간 급이한 시험군 1의 경우 비교시험군 1, 2, 3 및 대조군에 비해 낮은 총 콜레스테롤(TC) 함량, 높은 고밀도 리포단백질 콜레스테롤(HDL-C) 함량, 낮은 저밀도 리포단백질 콜레스테롤(LDL-C) 함량 및 낮은 트리글리세라이드 함량을 나타내어 간 기능 개선 효과를 나타내었다.
(TC) content and high-density lipoprotein cholesterol (HDL-C) content in the case of the test group 1 in which 0.2 ml of the lactic acid fermentation broth of the present invention and the high fat diet were fed for 5 weeks compared to the comparative test groups 1, 2, ), Low-density lipoprotein cholesterol (LDL-C) content and low triglyceride content.
그러나 글루코스의 경우 고지방 식이와 본 발명의 유산균 발효액 0.2ml를 5주간 급이한 시험군 1과 비교시험군 1, 2, 3 및 대조군 간에 유의미한 차이를 나타내지 않았다.
However, in the case of glucose, there was no significant difference between the test group 1 and the control test groups 1, 2 and 3 and the control group in which 0.2 ml of the lactic acid fermentation broth of the present invention and the high fat diet were fed for 5 weeks.
(실시예 3) 기호성 관능 시험
(Example 3) Palatability test
1. 음료 1의 제조
1. Preparation of beverage 1
제조실시예 1에서 제조된 유산균 발효액 100ml에 올리고당 5 중량%, 과당 3 중량%를 첨가한 후 전체 용량이 200ml가 되도록 정제수를 추가로 첨가시켜 음료 1을 제조한다.
5% by weight of oligosaccharide and 3% by weight of fructose were added to 100 ml of lactic acid fermentation broth prepared in Preparation Example 1, and purified water was further added thereto so that the total volume became 200 ml.
2. 음료 2의 제조
2. Preparation of beverage 2
제조실시예 2에서 제조된 유산균 발효액 100ml에 올리고당 5 중량%, 과당 3 중량%를 첨가한 후 전체 용량이 200ml가 되도록 정제수를 추가로 첨가시켜 음료 2를 제조한다.
5% by weight of oligosaccharide and 3% by weight of fructose were added to 100 ml of the lactic acid fermentation broth prepared in Preparation Example 2, and purified water was further added to make the total volume 200 ml.
3. 비교 음료 1의 제조
3. Preparation of Comparative Drink 1
제조비교예 1에서 제조된 유산균 발효액 100ml에 올리고당 5 중량%, 과당 3 중량%를 첨가한 후 전체 용량이 200ml가 되도록 정제수를 추가로 첨가시켜 비교 음료 1을 제조한다.
Preparation Comparative drink 1 was prepared by adding 5% by weight of oligosaccharide and 3% by weight of fructose to 100 ml of lactic acid fermentation broth prepared in Comparative Example 1 and further adding purified water so that the total volume became 200 ml.
4. 비교 음료 2의 제조
4. Preparation of Comparative Drink 2
제조비교예 2에서 제조된 유산균 발효액 100ml에 올리고당 5 중량%, 과당 3 중량%를 첨가한 후 전체 용량이 200ml가 되도록 정제수를 추가로 첨가시켜 비교 음료 2를 제조한다.
Preparation Comparative drink 2 was prepared by adding 5% by weight of oligosaccharide and 3% by weight of fructose to 100 ml of lactic acid fermentation broth prepared in Comparative Example 2, and adding purified water so that the total volume became 200 ml.
5. 비교 음료 3의 제조
5. Preparation of Comparative Drink 3
제조비교예 3에서 제조된 유산균 발효액 100ml에 올리고당 5 중량%, 과당 3 중량%를 첨가한 후 전체 용량이 200ml가 되도록 정제수를 추가로 첨가시켜 비교 음료 3을 제조한다.
Manufacturing Comparative drink 3 was prepared by adding 5% by weight of oligosaccharide and 3% by weight of fructose to 100 ml of lactic acid fermentation broth prepared in Comparative Example 3, and adding purified water so that the total volume became 200 ml.
음료 1, 2 및 비교음료 1, 2, 3에 대한 기호성을 관능검사원 10명을 선별하여 실시하였다. 기호성의 항목은 맛, 냄새, 음용감으로 나누어 측정하였으며 5(아주 좋음), 4(좋음), 3(보통), 2(나쁨), 1(아주 나쁨)을 나타내도록 5점 채점 척도법으로 측정하였다. 그 결과를 표 4에 나타내었다.
Ten palatability tests were conducted for the preference of beverages 1 and 2 and comparative beverages 1, 2 and 3. The items of palatability were measured by dividing them into taste, smell and tone of mouth and measured by 5 point scoring method to show 5 (very good), 4 (good), 3 (normal), 2 (poor) . The results are shown in Table 4.
제조실시예 2에서 제조된 유산균 발효액을 원료로 사용한 음료 2에서 가장 높은 기호성 관능 시험 결과가 측정되었다. 제조실시예 2에서 제조된 유산균 발효액은 실온에서 90일간 발효 숙성시켜 제조된 유산균 발효액으로 제조실시예 1에서 제조된 유산균 발효액보다 발효 숙성기간이 30일 증가된 것이다.
The highest palatability test results of beverage 2 using the lactic acid fermentation broth prepared in Preparation Example 2 as a raw material were measured. The lactic acid fermentation broth prepared in Preparation Example 2 was fermented by fermentation for 90 days at room temperature and fermentation aging period was increased by 30 days as compared with the fermentation broth prepared in Example 1.
한편 발효 숙성기간이 15일뿐인 제조비교예 2에서 제조된 유산균 발효액을 원료로 사용한 비교음료 2의 경우 음료 1, 2에 비해 맛, 냄새, 음용감이 모두 저하되는 측정 결과를 나타내었다. 또한 화학적 팽창제를 사용한 제조비교예 1의 유산균 발효액을 원료로 사용한 비교음료 1 및 통상의 유산균을 사용하여 발효시킨 제조비교예 3의 유산균 발효액을 원료로 사용한 비교음료 3 역시 본 발명의 음료 1, 2에 비해 낮은 맛, 냄새, 음용감을 나타내었다.
On the other hand, the comparative beverage 2 using the lactic acid fermentation broth prepared in Comparative Preparation Example 2 in which the fermentation period of fermentation was 15 days showed a decrease in taste, odor, and soundness compared to beverages 1 and 2. Preparation using a chemical swelling agent Comparative drink 1 using the lactic acid fermentation broth of Comparative Example 1 as a raw material and Comparative Beverage 3 using the lactic acid fermentation broth of Production Comparative Example 3 fermented using ordinary lactic acid bacteria were also used as beverages 1 and 2 , And a low taste, smell, and drinking sensation.
따라서 본 발명의 유산균 발효액을 사용하여 제조된 음료 1 및 음료 2는 건강기능성과 함께 높은 관능 기호성을 지닌 것으로 상업화 가능성이 증대된 것이다.
Therefore, the beverage 1 and the beverage 2 produced using the lactic acid fermentation broth of the present invention have a high functional palatability as well as a health functional property, and the possibility of commercialization is increased.
Claims (4)
ⅱ) 락토바실러스속 nhs221 균주(기탁번호 KCTC-11749BP호) 배양액 0.8~1.2 중량부(1.0 ~ 8.0 ×108 cfu/ml)를 넣어 실온에서 50~100일간 발효 숙성시켜 유산균 발효액을 수득하는 단계;
로 이루어진 유산균 발효액의 제조 방법에 있어서,
상기 생균제제는 류코노스톡(Leuconostoc) 속의 생균주(기탁번호 KCTC-11226BP호)와 사카로마이세스(Saccharomyces) 속의 효모균주(기탁번호 KCTC-11227BP호)를 혼합시킨 생균제제임을 특징으로 하는 비만 예방 및 체중 조절 효과를 지닌 유산균 발효액의 제조 방법.
I) 300 to 700 parts by weight of purified water is added to 100 parts by weight of the bread powder obtained by drying and crushing the bread prepared from the probiotic agent, and sugar and / or fructose are added to adjust the sugar content to 10-15 degrees Brix; And
Ii) 0.8 to 1.2 parts by weight (1.0 to 8.0 × 10 8 cfu / ml) of a culture of a strain of Lactobacillus sp. Nhs221 (accession number KCTC-11749BP) is fermented at room temperature for 50 to 100 days to obtain a lactic acid fermentation broth;
[Claim 10] A method for producing a lactic acid fermentation broth comprising:
The prophylactic agent is an obesity bacterium which is a probiotic agent in which a live host strain of Leuconostoc (Accession No. KCTC-11226 BP) and a yeast strain of Saccharomyces genus (Accession No. KCTC-11227 BP) A method for producing lactic acid fermentation broth having preventive and weight control effect.
[Claim 3] The method according to claim 1, wherein the Lactobacillus sp. Nhs221 strain (Accession No. KCTC-11749BP) is a strain of Lactobacillus sp. Strain which fermentes a large amount of lactic acid in a starch medium.
[Claim 3] The method according to claim 1, wherein the lactic acid fermentation broth has an effect of improving liver function by lowering the content of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol and triglyceride in a test animal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170017318A KR101884634B1 (en) | 2017-02-08 | 2017-02-08 | Lactobacillus fermented drink mixture having weight control effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170017318A KR101884634B1 (en) | 2017-02-08 | 2017-02-08 | Lactobacillus fermented drink mixture having weight control effect |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101884634B1 true KR101884634B1 (en) | 2018-08-02 |
Family
ID=63251364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170017318A KR101884634B1 (en) | 2017-02-08 | 2017-02-08 | Lactobacillus fermented drink mixture having weight control effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101884634B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020204832A1 (en) * | 2019-04-02 | 2020-10-08 | National University Of Singapore | A bread-based beverage |
WO2021006409A1 (en) * | 2019-07-11 | 2021-01-14 | Han Seung Noh | Health functional food product prepared by fermenting a dough containing whey |
KR20230137649A (en) * | 2022-03-22 | 2023-10-05 | 제이에스바이오컴퍼니 주식회사 | Manufacturing process of lactic acid bacteria fermentation broth through double culture process, kimchi using the same, and kimchi manufacturing process |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008222701A (en) * | 2007-03-09 | 2008-09-25 | Kangwon National Univ Industry Cooperation Foundation | Fermented product for preventing and treating obesity, fermented product for preventing diabetes, fermented food for preventing and treating obesity and food for preventing diabetes |
KR20150101558A (en) * | 2014-02-27 | 2015-09-04 | 나광출 | Anti-obesity health functional fermented soybean beverage having flavored taste |
-
2017
- 2017-02-08 KR KR1020170017318A patent/KR101884634B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008222701A (en) * | 2007-03-09 | 2008-09-25 | Kangwon National Univ Industry Cooperation Foundation | Fermented product for preventing and treating obesity, fermented product for preventing diabetes, fermented food for preventing and treating obesity and food for preventing diabetes |
KR20150101558A (en) * | 2014-02-27 | 2015-09-04 | 나광출 | Anti-obesity health functional fermented soybean beverage having flavored taste |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020204832A1 (en) * | 2019-04-02 | 2020-10-08 | National University Of Singapore | A bread-based beverage |
CN113923998A (en) * | 2019-04-02 | 2022-01-11 | 新加坡国立大学 | Bread-based beverage |
WO2021006409A1 (en) * | 2019-07-11 | 2021-01-14 | Han Seung Noh | Health functional food product prepared by fermenting a dough containing whey |
CN112566499A (en) * | 2019-07-11 | 2021-03-26 | 鲁翰升 | Functional health food product prepared by fermenting whey-containing dough |
US11596154B2 (en) | 2019-07-11 | 2023-03-07 | Han Seung NOH | Health functional food product prepared by fermenting a dough containing whey |
KR20230137649A (en) * | 2022-03-22 | 2023-10-05 | 제이에스바이오컴퍼니 주식회사 | Manufacturing process of lactic acid bacteria fermentation broth through double culture process, kimchi using the same, and kimchi manufacturing process |
KR102615346B1 (en) * | 2022-03-22 | 2023-12-19 | 제이에스바이오컴퍼니 주식회사 | Manufacturing process of lactic acid bacteria fermentation broth through double culture process, kimchi using the same, and kimchi manufacturing process |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2177110B1 (en) | Immunostimulating composition containing lactic acid bacteria | |
KR101287120B1 (en) | Composition comprising Lactobacillus plantarum DSR CK10 or Lactobacillus plantarum DSR M2 as an effective ingredient for treatment of cancer | |
WO2019112054A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
KR101825836B1 (en) | Novel Lactobacillus plantarum Lb41 strain and compositions for the prevention and treatment of diabetes or insulin resistance syndrome containing the same | |
KR101761379B1 (en) | Novel Lactobacillus sakei K040706 for multi function and culture method thereof | |
KR101680014B1 (en) | Lactic acid bacterium isolated from Kimchi for treating inflammatory bowel disease and uses thereof | |
CN107530387B (en) | Oral composition containing Bifidobacterium and cruciferous vegetable | |
KR20090049604A (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
TW200804591A (en) | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation | |
KR102543494B1 (en) | Novel probiotics and use thereof | |
KR101884634B1 (en) | Lactobacillus fermented drink mixture having weight control effect | |
CN115066188A (en) | Composition comprising a metal oxide and a metal oxide | |
KR102155849B1 (en) | Lactobacillus plantarum SRCM102369 strain having antimicrobial activity against pathogenic microorganism and lactic acid production ability and uses thereof | |
JP5229977B2 (en) | Blood adiponectin concentration increase promoting and / or decreasing inhibitor | |
JP4336930B2 (en) | Method for producing lactic acid bacteria fermentation broth and food made from the fermentation broth | |
KR101192673B1 (en) | Method for fermentation of mixed grains using fermentation micro-organisms (fm) and mass production of fermented grains | |
KR101515253B1 (en) | Agent for promoting the secretion of and/or suppressing decrease of adiponectin | |
WO2019188943A1 (en) | Composition for preventing and/or ameliorating decrease in brain blood flow | |
KR101421284B1 (en) | Composition for Improving Constipation and Manufacturing Method thereof | |
KR101779719B1 (en) | Novel Lactobacillus kefiranofaciens DN1 and composition for treating or preventing constipation comprising the same | |
JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
JP2010209015A (en) | Composition for anti-allergy, and anti-allergic agent and anti-allergic food containing the same | |
JP2010155789A (en) | Hepatic function disorder-improving agent | |
KR102244732B1 (en) | Probiotic acetic acid bacteria Acetobacter pasteurianus MGLV and its immunomodulatory effect | |
KR20190048739A (en) | Lactobacillus johnsonii IDCC9203 having effect of preventing and improving inflammation, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |